Evidence map›Paper›PMID 35127536›Full record

ArticleFrontiers in oncology2021

The Addition of Ferritin Enhanced the Prognostic Value of International Prognostic Index in Diffuse Large B-Cell Lymphoma.

Ziyuan Shen, Shuo Zhang, Meng Zhang, Lingling Hu, Qian Sun, Chenlu He, Dongmei Yan, Jingjing Ye, Hao Zhang, Ling Wang and 9 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Macrophage ferroptosis in hematologic malignancies: emerging mechanisms and therapeutic implications.Apoptosis : an international journal on programmed cell death · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 1 country.

Ziyuan ShenDepartment of Epidemiology and Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, China.
Shuo ZhangDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Meng ZhangDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Lingling HuDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Qian SunDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Chenlu HeDepartment of Epidemiology and Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, China.
Dongmei YanDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jingjing YeDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Hao ZhangDepartment of Hematology, The Affiliated Hospital of Jining Medical University, Jining, China.
Ling WangDepartment of Hematology, Taian Central Hospital, Taian, China.
Weiying GuDepartment of Hematology, The First People's Hospital of Changzhou, Changzhou, China.
Yuqing MiaoDepartment of Hematology, Yancheng First People's Hospital, Yancheng, China.
Qinhua LiuDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Changli OuyangDepartment of Nuclear Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Junfeng ZhuDepartment of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Chunling WangDepartment of Hematology, Huai'an First People's Hospital, Huaian, China.
Taigang ZhuDepartment of Hematology, The General Hospital of Wanbei Coal-Electric Group, Suzhou, China.
Shuiping HuangDepartment of Epidemiology and Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, China.
Wei SangDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xuzhou Medical College · CNAffiliated Hospital of Jining Medical University · CNAnhui Medical University · CNFirst Affiliated Hospital of Bengbu Medical College · CNHuaian First People’s Hospital · CNNantong University · CNQilu Hospital of Shandong University · CNTaian City Central Hospital · CNThe First People's Hospital of Changzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous non-Hodgkin lymphoma, and the prognosis of DLBCL patients is widely affected by multivariables. Clinical-factors-based prognostic systems stratify the prognosis of DLBCL with certain limitations, and the value of ferritin on the prognosis of DLBCL is unclear. In this study, 225 cases were retrieved from 4 centers of Huaihai Lymphoma Working Group (HHLWG) as the derivation cohort, and 66 cases were from the other 6 centers of HHLWG as external validation cohort. X-Tile program divided ferritin into three groups when applying 175.00 and 391.90 μg/L as the optimal cutoff points. Based on multivariable analysis, ferritin appeared to be a stronger predictor. A total of three variables (ferritin, age, and lactate dehydrogenase) were included for the development of the nomogram. The C-indexes were 0.73 and 0.70 in the derivation and validation cohort, and the calibration curve showed the consistency between the nomogram prediction and the actual observation. In conclusion, Ferritin-based nomogram enhanced the prognostic value of IPI in DLBCL.

Indexed as

DLBCLferritinInternational Prognostic Indexnomogramprognosis

Identifiers

PMID35127536
PMCPMC8807645
OpenAlexW4205420402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.